US government agencies have questioned the legality of cannabidiol (CBD) – just as the industry is starting to see the benefits of increased public awareness.
Actions by both the US Food and Drug Administration (FDA) and the US Drug Enforcement Administration (DEA) have recently cast doubt on the future of CBD, according to speakers at the Marijuana Business Conference (MJBizCon) held May 9th–11th in New Orleans.
The situation is further complicated by the lack of clarity over the status of CBD, as some stakeholders classify it as a drug and others as a dietary supplement. Speakers at the conference also discussed a potential loophole that would allow CBD to be legally sold as a product derived from industrial hemp.
Sign up to access to our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
